News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
177,511 Results
Type
Article (13211)
Company Profile (26)
Press Release (164274)
Section
Business (49791)
Career Advice (618)
Deals (9249)
Drug Delivery (34)
Drug Development (28453)
Employer Resources (70)
FDA (4758)
Job Trends (3924)
News (92841)
Policy (7984)
Tag
Academia (1078)
Alliances (14093)
Alzheimer's disease (423)
Approvals (4759)
Artificial intelligence (49)
Bankruptcy (69)
Best Places to Work (3242)
Biosimilars (41)
Breast cancer (68)
Cancer (467)
Cardiovascular disease (44)
Career advice (517)
CAR-T (39)
Cell therapy (96)
Clinical research (24006)
Collaboration (146)
COVID-19 (1078)
C-suite (41)
Data (561)
Diabetes (76)
Diagnostics (1696)
Drug pricing (47)
Earnings (14337)
Employer resources (64)
Events (20964)
Executive appointments (159)
FDA (5009)
Funding (168)
Gene therapy (73)
GLP-1 (281)
Government (1184)
Healthcare (5444)
Infectious disease (1115)
Inflammatory bowel disease (50)
Interviews (105)
IPO (3502)
Job creations (812)
Job search strategy (458)
Layoffs (83)
Legal (1577)
Lung cancer (59)
Manufacturing (60)
Medical device (3143)
Medtech (3145)
Mergers & acquisitions (5858)
Metabolic disorders (196)
Neuroscience (568)
NextGen: Class of 2025 (2027)
Non-profit (1646)
Northern California (427)
Obesity (97)
Opinion (50)
Parkinson's disease (46)
People (17621)
Phase I (5351)
Phase II (10300)
Phase III (9745)
Pipeline (187)
Policy (45)
Postmarket research (1209)
Preclinical (1912)
Radiopharmaceuticals (62)
Rare diseases (91)
Real estate (1405)
Regulatory (5752)
Research institute (901)
Resumes & cover letters (82)
Series A (43)
Southern California (396)
Startups (1204)
United States (4044)
Vaccines (265)
Weight loss (74)
Date
Last 7 days (153)
Last 30 days (678)
Last 365 days (8549)
2025 (1159)
2024 (8623)
2023 (9760)
2022 (13255)
2021 (14811)
2020 (14300)
2019 (13759)
2018 (10627)
2017 (9760)
2016 (9356)
2015 (11019)
2014 (7555)
2013 (5950)
2012 (6396)
2011 (6745)
2010 (5808)
Location
Africa (262)
Arizona (38)
Asia (12542)
Australia (2409)
California (994)
Canada (327)
China (118)
Colorado (48)
Connecticut (52)
Europe (34399)
Florida (142)
Georgia (64)
Illinois (131)
Indiana (74)
Japan (52)
Maryland (191)
Massachusetts (669)
Minnesota (74)
New Jersey (336)
New York (394)
North Carolina (165)
Northern California (427)
Pennsylvania (236)
South America (380)
Southern California (396)
Texas (118)
Washington State (142)
177,511 Results for "boehringer mannheim group".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Boehringer Ingelheim’s Lung Fibrosis Drug Scores Second Late-Stage Win
Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary fibrosis—nearly six months after achieving a similar feat in idiopathic pulmonary fibrosis. Boehringer plans to submit for FDA and other global approvals in both indications.
February 10, 2025
·
2 min read
·
Heather McKenzie
Collaboration
Boehringer Ingelheim Expands Cancer Pipeline With Back-to-Back Antibody Deals
On Thursday, Boehringer Ingelheim announced a partnership with Synaffix to advance antibody-drug conjugates and exercised its fourth license option under a 2013 collaboration with Oxford BioTherapeutics.
January 10, 2025
·
2 min read
·
Tristan Manalac
Schizophrenia
Boehringer Suffers Phase III Schizophrenia Fail, Legal Parry by HHS
Boehringer Ingelheim’s trio of late-stage schizophrenia failures on Thursday came a day after the Department of Health and Human Services hit back on the pharma’s legal challenge to the IRA’s drug price negotiation program.
January 17, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Boehringer’s nerandomilast meets primary endpoint in Phase III study FIBRONEER™-ILD, in progressive pulmonary fibrosis
February 10, 2025
·
7 min read
Press Releases
Boehringer Canada Announces Availability of SPEVIGO® for expanded indication in Canada
February 6, 2025
·
7 min read
Press Releases
Boehringer provides update on iclepertin Phase III program in schizophrenia
January 16, 2025
·
5 min read
Drug development
Boehringer, Insilico Appear to Break Through Against IPF
Clinical trial results shared by Boehringer Ingelheim and Insilico Medicine showed improvement in idiopathic pulmonary fibrosis, an intractable lung disease for which current treatment options fail to stop progression, but the data were limited, leaving experts wanting.
September 24, 2024
·
4 min read
·
Heather McKenzie
Press Releases
Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled gene therapy for people with cystic fibrosis
February 21, 2025
·
8 min read
Phase III
Boehringer Aces Phase III Pulmonary Fibrosis Trial, Plans FDA Application
Boehringer Ingelheim’s investigational compound nerandomilast, which targets the PDE4B enzyme involved in fibrosis and inflammation in the lungs, met its primary endpoint in a late-stage study.
September 17, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Boehringer Ingelheim Pharmaceuticals, Inc. Welcomes Brian Hilberdink as President, U.S. Human Pharma
February 20, 2025
·
2 min read
1 of 17,752
Next
